Erlotinib
Erlotinib
The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
Products Information
| RX PRODUCT | NDC# | STRENGTH | SIZE | PRODUCT CLASS | ADMINISTRATION | CASE SIZE |
|---|---|---|---|---|---|---|
| Erlotinib | 59923-725-30 | 25 mg | 30 | Antineoplastic | Oral | N.A |
| Erlotinib | 59923-726-30 | 100 mg | 30 | Antineoplastic | Oral | N.A |
| Erlotinib | 59923-727-30 | 150 mg | 30 | Antineoplastic | Oral | N.A |
| Wholesaler | Erlotinib 25mg | Erlotinib 100mg | Erlotinib 150mg |
|---|---|---|---|
| AmerisourceBergen | 10236033 | 10236032 | 10236031 |
| Cardinal | 5680640 | 5680657 | 5680665 |
| McKesson | 1573575 | 1573625 | 1573641 |
Download Product Information